Cargando…
A New Venue of TNF Targeting
The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies. Conventional antibodies bind a specific protein and are becoming increasingly importan...
Autores principales: | Steeland, Sophie, Libert, Claude, Vandenbroucke, Roosmarijn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983675/ https://www.ncbi.nlm.nih.gov/pubmed/29751683 http://dx.doi.org/10.3390/ijms19051442 |
Ejemplares similares
-
Choroid plexus tumor necrosis factor receptor 1: a new neuroinflammatory piece of the complex Alzheimer’s disease puzzle
por: Steeland, Sophie, et al.
Publicado: (2019) -
Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1
por: Puimège, Leen, et al.
Publicado: (2015) -
A Study of Cecal Ligation and Puncture-Induced Sepsis in Tissue-Specific Tumor Necrosis Factor Receptor 1-Deficient Mice
por: Vandewalle, Jolien, et al.
Publicado: (2019) -
Topical imiquimod yields systemic effects due to unintended oral uptake
por: Grine, Lynda, et al.
Publicado: (2016) -
Counteracting the effects of TNF receptor‐1 has therapeutic potential in Alzheimer's disease
por: Steeland, Sophie, et al.
Publicado: (2018)